Needham & Company Cuts Price Target on Flexion Therapeutics (FLXN) Following Top-Line FX006 Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
After-Hours Stock Movers 09/08: (ABKA) (VTAE) (PLAY) Higher; (TTPH) (ZQK) (FLXN) (PSUN) Lower (more...)
September 8, 2015 5:33 PM EDTTetraphase Pharma (NASDAQ: TTPH) 79.5% LOWER; announced that the IGNITE2 phase 3 clinical trial of eravacycline administered as an IV to oral transition therapy for the treatment of complicated urinary tract infections (cUTI) did not achieve its primary endpoint of statistical non-inferiority compared to levofloxacin.
Akebia Therapeutics, Inc. (NASDAQ: AKBA) 61.3% HIGHER; announced positive top-line results from its Phase 2 study of vadadustat (formerly AKB-6548) in dialysis patients with anemia related to chronic kidney disease (CKD). The study achieved its primary objective, indicating that vadadustat maintained stable... More
Ampio Pharma (AMPE) Mentioned Cautiously in Connection with Flexion's Trial Failure
September 8, 2015 5:26 PM EDTAmpio Pharma (NYSE: AMPE) was mentioned cautiously in connection with Flexion Therapeutics' (NASDAQ: FLXN) failed FX006 trial. Given the blow up, Ampio Pharma should trade at zero, said theStreet.com's Adam Feuerstein.
Given the $FLXN blow up, $AMPE should trade at zero. Literally, zero.
Adam Feuerstein (@adamfeuerstein) September 8, 2015... More
Flexion Therapeutics (FLXN) Announces First Phase 2b of FX006 in OA Knee Pain Missed Primary Endpoint
September 8, 2015 4:07 PM EDTFlexion Therapeutics (NASDAQ: FLXN) reported top-line results from the first of two pivotal clinical trials of its lead drug candidate FX006 in patients with moderate to severe osteoarthritis (OA) knee pain. In this trial, 40 mg of FX006, compared to placebo (saline), demonstrated statistical significance in average pain relief over weeks 1 through 12 (p = 0.0012; 2-sided) and over weeks 1 through 24 (p = 0.0209; 2-sided). At weekly time points, 40 mg of FX006 also demonstrated superiority to placebo in pain relief beginning at week 1, continuing to week 11 and also at week 13 (p... More
